Peptides Weekly Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. What You Need to Know: Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. Political Wire, quoting The Washington Post, describes a drafting process for previously restricted peptides, not a completed approval and not a patient trial. ... Sources: washingtonpost.com · stocktwits.com · ascopost.com · amp.sacbee.com · foodnavigator.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. If this episode was useful, a rating or a short review on Apple Podcasts or Spotify is how the next listener finds the show — and following it in your app means the next episode is there when you are. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.
続きを読む
一部表示